

Orabloc®

Articaine hydrochloride 40mg/ml
and epinephrine bitartrate injection
0.018mg/ml or 0.009mg/ml



Discover Orabloc®

- » The anaesthesia is obtained rapidly (1 to 3 minutes) and lasts from 45-75 minutes per cartridge¹.
- » Reactions to Orabloc are characteristic of amide-type local anaesthetics.
- » 24 month shelf life at room temperature.
- » Sodium edetate free, methylparaben free and latex free.
- » Each cartridge is sealed individually in the blister for maximum protection.

¹Clinical significance has not been established.

Orabloc (articaine hydrochloride) is indicated for infiltration anaesthesia and nerve block anaesthesia in clinical dentistry

Includes local or loco-regional anaesthesia suitable for operations such as: single extractions, with no complications; multiple extractions; extractions for impacted teeth; trephinement; apical resections; removal of cysts; alveolectomies; preparation of cavity; biopulpectomies; and maxillo-facial surgery.

Also suitable for muco-gingival operations and other surgical operations on the bone when long lasting ischaemia and analgesia are required.

Articaine hydrochloride 40mg/ml and epinephrine bitartrate injection 0.018mg/ml or 0.009mg/ml

An aseptically manufactured articaine

Dosage and administration - Adults

- For most common operations, one infiltration with 1.7 ml Orabloc is sufficient. In all cases, the injection must be administered slowly (about 1 mL/min).
- For an infiltration in the interdental septum, a quantity of 0.3 to 0.5 ml is indicated as generally sufficient.
- Do not exceed the equivalent of 7 mg articaine hydrochloride per kilogram body weight. The duration of anaesthesia during which an operation can be performed using Orabloc 1:200,000 is up to 45 minutes. The duration of anaesthesia during which an operation can be performed using Orabloc 1:100,000 is up to 75 minutes. The lowest dosage needed to provide effective anaesthesia should be administered.
- Please see the Product Monograph for complete dosing and administration information

Pediatric Patients

- For Orabloc 1:200,000 and Orabloc 1:100,000 use in children under 4 years of age is not recommended.
- The quantity to be injected should be determined by the age of the child and the size of the operation.
- » Do not exceed the equivalent of 7 mg articaine hydrochloride per kilogram of body weight.

Contraindications

- » Known allergies to dental anesthetics.
- » Sepsis near the proposed injection site.
- » Severe shock.
- » Paroxysmal tachycardia.
- » Frequent arrhythmia.
- » Severe hypertension.
- » Neurological diseases.
- » Asthma who may have bronchospastic allergic reactions induced by sulphites.

Relevant Warnings and Precautions

- » Orabloc is capable of producing methemoglobinemia.
- » Orabloc contains sulphites which can cause or aggravate anaphylactic-type reactions.
- » Intravascular injections are strictly contraindicated.
- » Toxic reactions may occur in the case of overdosage or accidental intravenous injection.
- » The American Heart Association recommends using vasoconstrictor agents in patients with ischemic disease only when it is clear that the procedure will be shortened or the analgesia rendered more profound.
- » The minimum possible amount of vasoconstrictor should be used.
- » When injecting a local anesthetic, anti-convulsant medicines, myorelaxants, atropine, vasopressors, resuscitating equipment enabling artificial ventilations should be available.
- » Orabloc should be given cautiously in patients with known or suspected drug allergies or sensitivities to amide-type local anaesthetics.
- » Avoid injections into an inflamed or infected area.
- » Injections should be made slowly.
- » The lowest dosage (volume and concentration) should be used.
- » The actual dosage and maximum dosage must be individualized.
- » Absorption is greater in highly vascular tissue.
- » Avoid excessive premedication with sedatives, tranquilizers and anti-emetic agents especially in small children and elderly.
- » Use with caution in patients with peripheral vascular disease or injection into areas with limited blood supply.
- » Orabloc is not advised for diabetic patients due to the presence of epinephrine.
- » Allergic-type reactions may occur in patients with bronchial asthma.
- » Careful consideration should be given before administering local anaesthetics in pregnant women.

For more information

Please consult the Orabloc Product Monograph at <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp> for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece.



To learn more about Orabloc call
Pierrel at 1-610-989-4222
or email to orabloc@pierrelgroup.com